Halozyme Pricing Upsized $1.3B Convertible Note Offering

Halozyme Therapeutics priced an upsized, $1.3 billion private offering of 1.50% convertible senior notes due 2033, increasing the size from a previously announced $1.05 billion. The notes are senior, unsecured obligations being offered exclusively to qualified institutional buyers.